Outcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over Medical Therapy as an Early Intervention for BPH
May 07, 2024 06:30 ET
|
Teleflex Incorporated
WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024...
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
April 02, 2024 06:30 ET
|
Teleflex Incorporated
WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced...
Large-Scale Real-World Study Demystifies UroLift™ System Durability and Reinforces Superior Patient Experience for Men With Enlarged Prostate Compared to Leading Surgical Treatments
November 14, 2023 06:45 ET
|
Teleflex Incorporated
WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature...
New Survey Highlights the Quality of Life Impact of an Enlarged Prostate
September 12, 2023 06:30 ET
|
Teleflex Incorporated
WAYNE, Pa., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced results of its new survey showing that symptoms...
New Data Highlight that Early Intervention with the UroLift® System Facilitates Long-Term Outcomes for BPH Patients
May 03, 2023 06:30 ET
|
Teleflex Incorporated
WAYNE, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced new research findings reinforcing the long-term...
Teleflex Launches National Ad Campaign — “Pit Stop” — to Raise Awareness of the UroLift® System as a Treatment for Enlarged Prostate
February 06, 2023 06:30 ET
|
Teleflex Incorporated
WAYNE, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the launch of a new national advertising campaign...
Published Data Demonstrate Consistent PUL Outcomes for the Treatment of Median Lobe Obstruction Across Controlled and Real-World Settings
October 25, 2022 06:30 ET
|
Teleflex Incorporated
Men with obstructive median lobes treated with the UroLift® System experience symptom improvement sooner and are satisfied more quickly compared to those treated with TURP, and have fewer post-op...
Teleflex Announces Collaboration with FundamentalVR, to Improve Training Through Virtual Reality Simulation
August 25, 2022 06:30 ET
|
Teleflex Incorporated
FundamentalVR Offers Teleflex a Scalable Training Platform to Accelerate the Effective Use of the UroLift® 2 System for Treatment of Enlarged Prostate WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) --...
Teleflex Announces Pocono Raceway NASCAR Event to Raise Visibility of Enlarged Prostate and the Importance of Regular Health Screenings
July 21, 2022 06:30 ET
|
Teleflex Incorporated
WAYNE, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the company is hosting a booth at the Pocono...
New Data Reinforce Efficacy of the UroLift® System for the Treatment of Enlarged Prostate
July 01, 2022 06:30 ET
|
Teleflex Incorporated
WAYNE, Pa., July 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the results of several research studies that...